Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QR12000 (Wuhan Createrna Science and Technology Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Wuhan Createrna Science and Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**QR12000** is an oral fixed-dose angiotensin receptor-neprilysin inhibitor developed by Wuhan Createrna Science and Technology for essential hypertension. The tablet combines **QR01019 potassium salt**, a novel azilsartan prodrug that is converted to azilsartan and selectively antagonizes the angiotensin II type 1 receptor, with **sacubitril ammonium salt**, a neprilysin inhibitor prodrug. This dual mechanism is intended to reduce vasoconstrictive and sodium-retentive angiotensin II signaling while augmenting natriuretic-peptide activity. The sponsor reports that QR12000 has completed a Phase II study and is in Phase III development for primary essential hypertension. ([createrna.com](https://createrna.com/news-activity/news-center/news/53))
- Other names
- QR12000 Compound TabletsQR-12000 Compound TabletsQR 12000 Compound Tablets
02
Targets
NEP (Neutral Endopeptidase)AGTR2 (AT2)
Beyond the preview
Go deeper on QR12000 (Wuhan Createrna Science and Technology Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QR12000 (Wuhan Createrna Science and Technology Co., Ltd.).